Merus to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference
Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, announced that CEO Bill Lundberg will speak at the Stifel 2022 Healthcare Conference on November 16, 2022, at 1:50 p.m. ET. The presentation will be available via webcast on the company's Investors page and archived for later viewing. Merus specializes in developing full-length multispecific antibodies, known as Biclonics® and Triclonics®, with potential applications in oncology.
- None.
- None.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Stifel 2022 Healthcare Conference on Wednesday, November 16, 2022 at 1:50 p.m. ET.
The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and Twitter.
FAQ
What event will Merus N.V. participate in on November 16, 2022?
Who will represent Merus N.V. at the Stifel conference?
What time is Merus N.V.'s presentation at the Stifel Healthcare Conference?
How can I access the Merus N.V. presentation from the Stifel conference?
What type of products does Merus N.V. develop?
